Icade stock steadies as 2025 guidance and asset disposals reshape the French REIT

Icade stock is trading through a transition phase as the French real estate group (ISIN FR0000035081) reshapes its portfolio around healthcare and asset disposals after reporting revenue of about EUR 1.47 billion in 2024 and a lower recurring cash flow base, according to the company disclosures dated 20 February 2025. For investors, the balance between disposals, leverage, and dividends now drives the medium term more than short-term price moves.

Revenue at EUR 1.47 billion in 2024

According to the 2024 full-year results published by Icade on 20 February 2025, the group generated consolidated revenue of around EUR 1.47 billion for fiscal 2024, down from roughly EUR 1.51 billion in 2023 as office disposals weighed on the top line while healthcare and property development partly offset the decline. The company reported net current cash flow from the group share of approximately EUR 3.31 per share in 2024, compared with about EUR 4.16 per share in 2023, reflecting both asset sales and higher financing costs in a high-rate environment.

Icade highlighted that its group share net recurrent income reached roughly EUR 229 million in 2024, versus around EUR 288 million a year earlier, as the contraction in office income and the impact of disposals more than offset growth in healthcare revenues. Management pointed to a continued strong contribution from the healthcare activities, with healthcare real estate revenues rising in the low single digits on an organic basis in 2024, even as the broader French commercial property market remained under pressure.

Guidance and deleveraging shape 2025 outlook

For 2025, Icade has guided to net current cash flow from the group share in a range that implies a modest decline versus the 2024 base, signaling that deleveraging and selective capex will remain a priority. In its 20 February 2025 outlook comments, the company indicated that net current cash flow per share is expected to fall in a mid-single-digit percentage range compared with the EUR 3.31 achieved in 2024, assuming stable portfolio valuations and no major macroeconomic shock.

The real estate group is also pursuing disposals to reduce leverage. As of the end of 2024, Icade reported a loan-to-value (LTV) ratio on a group share basis in the low- to mid-40 percent area, slightly lower than the prior year after a program of office asset sales, while reiterating an objective of keeping LTV around or below the mid-40 percent threshold over the medium term. The company emphasized that it completed more than EUR 400 million of asset disposals in 2024, mainly in the office segment, at discount levels broadly consistent with previous external valuations, which it framed as evidence of the portfolio’s liquidity.

Dividend of EUR 2.37 per share

Icade’s board proposed a dividend of EUR 2.37 per share for the 2024 financial year, according to the 20 February 2025 earnings release, slightly below the EUR 2.42 per share distributed for 2023. The proposal corresponds to a payout ratio of around 72 percent of 2024 net current cash flow per share, down from approximately 58 percent the year before, as recurring earnings declined faster than the dividend.

The company noted that the dividend level aims to balance shareholder returns with the need to fund its pipeline in healthcare real estate and property development without stretching the balance sheet. From an investor perspective, that means the cash yield on Icade stock remains a central part of the total-return profile, especially at a time when the share price trades at a discount to reported net asset value (NAV) per share, according to the latest investor presentations.

Healthcare real estate supports the portfolio

Icade’s healthcare real estate arm has become the group’s key growth driver, with the segment providing more than 50 percent of the group’s net current cash flow in 2024, based on the latest segment disclosure. The company reported that the healthcare portfolio’s occupancy rate stayed above 95 percent throughout 2024, underpinning predictable rental income even as some office markets experienced rising vacancy rates.

In its 2024 communication, Icade highlighted that its healthcare pipeline includes several hundred million euros of committed investments in clinics and senior-care facilities over the next few years, with an average initial yield in the mid-4 percent range. For the broader group, the strategy is to gradually tilt the asset mix further toward healthcare and resilient rental cash flows, while continuing to reduce exposure to more cyclical office markets.

Icade stock and valuation context

On the primary listing in Paris, Icade stock recently traded in the mid-EUR 30s, giving the company a market capitalization in the low-single-digit billion-euro range as of early 2025, according to data from French market portals. This compares with a reported EPRA net tangible asset (NTA) per share in the low-EUR 50s at the end of 2024, implying a discount of roughly 30 percent or more to the underlying property values on that metric.

For investors focused on listed European real estate, that discount, combined with the EUR 2.37 per share dividend proposal for 2024, frames a risk-reward profile tied to the pace of interest-rate normalization, the execution of asset disposals, and the resilience of healthcare tenants. If interest rates ease and transaction markets remain open, the gap between the Icade share price and its reported net asset values could narrow over time; if financing costs stay elevated, asset values may remain under pressure and keep the discount wide.

Healthcare facilities as a representative asset type

A representative asset type for Icade is a modern private hospital or clinic within its healthcare real estate portfolio, often operated under long-term triple-net leases to medical groups or specialized operators. These properties tend to have long average lease maturities and index-linked rents, which provides visibility on cash flows and is a key reason why healthcare is at the center of Icade’s strategic repositioning. In its latest disclosures, the company pointed to continued demand for such assets driven by demographic aging and the need for upgraded medical infrastructure across France and other European markets.

Icade stock price snapshot

On Euronext Paris, Icade stock most recently changed hands in the mid-EUR 30s range in early 2025, according to quote data from French exchange portals, reflecting investor caution toward office-heavy real estate names but recognition of the stabilizing effect of healthcare assets and the EUR 2.37 per share dividend proposal for 2024. At that level, the shares trade at a sizeable discount to reported EPRA NTA per share in the low-EUR 50s at the end of 2024, underscoring how macro conditions and sector sentiment continue to influence valuation more than short-term earnings fluctuations.